Results
Thirty-two patients (median age: 61.5 years) were enrolled.
Co-administration of capmatinib increased digoxin Cmax,
and AUCinf by 74%, and 47%, respectively.
Co-administration of capmatinib increased rosuvastatin
Cmax, and AUCinf by 204%, and 108%,
respectively. Most frequent adverse events (AEs; ≥25% for all grades)
were nausea (56.3%), asthenia (43.8%), constipation and vomiting
(40.6%, each), peripheral edema (28.1%) and pyrexia (25%). Most
frequent Grade 3/4 AEs (≥5%) were anemia and pulmonary embolism (9.4%,
each), asthenia, dyspnea, nausea and vomiting (6.3%, each).